@article {7987,
	title = {Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus},
	journal = {European Journal of Gynaecological Oncology},
	volume = {26},
	year = {2005},
	note = {Cited By :5Export Date: 21 February 2017},
	month = {2005},
	pages = {627 - 631},
	abstract = {Purpose of investigation: Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent more aggressive tumors than the more common endometroid cancers, exhibiting a propensity for distant metastasis. The aim of this study was to investigate the activity and safety of paclitaxel/carboplatin chemotherapy as the only adjuvant treatment in patients with surgically resected UPSC and UCCC. Methods: Fifteen patients with Stage IB-IV UPSC or UCCC were treated with a mean of six courses of paclitaxel 175 mg/m3 plus carboplatin AUC 5 at three-week intervals, three to six weeks after undergoing surgery with curative intent. No patient had residual disease after surgery and none underwent pre- or post-chemotherapy irradiation. Results: With a median follow-up of 29.4 months, six patients (40\%) relapsed and two (13\%) died of disease. Mean time to recurrence was 16.9 months. Recurrence rate per Stage was 17\% for Stage IB/C, 57\% for Stage IIIA/C and 50\% for Stage IV. Projected 5-year overall survival and progression-free survival was 79.7\% and 55.7\%, respectively. All relapses were abdominopelvic whereas in one case pelvic recurrence was accompanied by lung metastasis. The most frequent grade 3-4 toxicity was neutropenia. Conclusion: Chemotherapy with paclitaxel plus carboplatin is feasible and possibly prevents distant metastasis when used as adjuvant in UPSC and UCCC.},
	keywords = {Adjuvant chemotherapy, Endometrial cancer, Paclitaxel, Uterine clear cell carcinoma, Uterine papillary serous carcinoma},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-29844446045\&partnerID=40\&md5=958e40df53ef85616a1e96bda15b0617},
	author = {Bozas, G.T. and Bamias, A. and Kastritis, E. and Rodolakis, A. and Vlahos, G. and Papadimitriou, C.A. and Markaki, S. and Dimopoulos, M.A.}
}
